Citations

Showing 10 of 108094 citations.

Asthma: Who’s Really in Control?
Schmelzer, Anna, Mott, Melissa L., Nguyen, Mary , Matheka, Faith, Boss, Victoria, Strelow, Brittany , Olson, Rachel , O’Laughlin, Danielle , DeJesus, Ramona S. , Mott, Melissa, Strelow, Brittany A , Mott, Melissa

Mayo Clinic

American Journal of Medical Quality | August 5, 2022 | Volume: 37 | Issue: 5 | Pages: 479-480

10.1097/jmq.0000000000000076 | PMID 35921124 Get It

High-fidelity control of spin ensemble dynamics via artificial intelligence: from quantum computing to NMR spectroscopy and imaging
Subrahmanian, Manu Veliparambil , Pavuluri, KowsalyaDevi , Olivieri, Cristina , Veglia, Gianluigi , Veglia, Gianluigi

Mayo Clinic

PNAS Nexus | August 5, 2022 | Volume: 1 | Issue: 4 | Pages: No page available

10.1093/pnasnexus/pgac133 | PMID 36106184 Get It

Abstract High-fidelity control of spin ensemble dynamics is essential for many research areas, spanning from quantum computing and radio-frequency (RF) engineering to NMR spectroscopy and imaging. However, attaining robust and high-fidelity spin operations remains an unmet challenge. Using an evolutionary algorithm and artificial intelligence (AI), we designed new RF pulses with customizable spatial or temporal field inhomogeneity compensation. Compared with the standard RF shapes, the new AI-generated pulses show superior performance for bandwidth, robustness, and tolerance to field imperfections. As a benchmark, we constructed a spin entanglement operator for the weakly coupled two-spin-1/2 system of 13CHCl3, achieving high-fidelity transformations under multiple inhomogeneity sources. We then generated band-selective and ultra-broadband RF pulses typical of biomolecular NMR spectroscopy. When implemented in multipulse NMR experiments, the AI-generated pulses significantly increased the sensitivity of medium-size and large protein spectra relative to standard pulse sequences. Finally, we applied the new pulses to typical imaging experiments, showing a remarkable tolerance to changes in the RF field. These AI-generated RF pulses can be directly implemented in quantum information, NMR spectroscopy of biomolecules, magnetic resonance imaging techniques for in vivo and materials sciences.
MERGING ADVANCE TECHNOLOGY TO IMPROVE OUTCOMES IN HEART TRANSPLANTATION - A CASE REPORT
Jang, Jin Sung , Pham, S, JM, Ruiz, PC, Patel, JC, Leoni, DS, Yip, JN, Nativi, Landolfo, K, Sareyyupoglu, B, RM, Goswami, Pham, S., Ruiz, Jose , Patel, Parag C. , Leoni, Juan Carlos , Yip, Daniel , Nativí, Jose, Landolfo, Kevin , Sareyyüpoğlu, Başar , Goswami, Rohan

Mayo Clinic

INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH | August 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: 26-28

10.36106/ijsr/5822267 Get It

One of the signicant obstacles to donor heart utilization is that increasingly prolonged cold ischemic times are associated with worsened short- and long-term outcomes. As a result, most transplant centers aim to limit cold ischemic times to less than four hours. The TransMedics Organ Care System (OCS) (Trans Medics, Andover MA) is a portable ex vivo perfusion system designed to store a donor heart in a beating, metabolically active state, until it reaches the recipient, thereby allowing extended time outside the body while minimizing the effects of cold storage. We present a case of a heart transplant recipient supported with the Impella 5.5 as a bridge to transplantation who received a donation after circulatory death (DCD) heart supported by OCS. To our knowledge, this is the rst report of such a case.
Risk of Sudden Death in a General Unbiased Epidemiological Cohort of Sarcoidosis
Chahal, C. Anwar A. , Brady, Peter A. , Lin, Grace , Somers, Virend K. , Crowson, Cynthia S. , Matteson, Eric L. , Ungprasert, Patompong , Cooper, Leslie T , Lin, Grace , Somers, Virend K. , Chahal, Choudhary Anwar A , Cooper, Leslie T.

Mayo Clinic

Journal of the American Heart Association | August 5, 2022 | Volume: 11 | Issue: 16 | Pages: No page available

10.1161/jaha.122.025479 | PMID 35929471 Get It

Background Sarcoidosis is an inflammatory, noncaseating, granulomatous disorder of unknown cause that can affect any body system and is associated with cardiovascular disease including sudden cardiac death (SCD). Cardiac involvement in sarcoidosis is associated with higher risk of SCD, but the SCD risk in the general sarcoidosis population is unknown. We aimed to determine the risk of SCD in people with sarcoidosis versus the matched general population. Methods and Results A population‐based cohort of sarcoidosis and age‐ and sex‐matched comparators from January 1, 1976 to December 31, 2013 was used; presence of other comorbidities in the comparator group was not an exclusion criterion. Mortality, including time, place, and cause of death were measured and manually adjudicated for SCD events. Incidence rates are reported per 100 000 person‐years, and Cox models were used for group comparisons. Of the 345 incident cases of sarcoidosis (171 men; 50%) there were 58 reported deaths; 10 were definite/probable SCD versus 57 all‐cause and 9 SCDs in comparators. Median follow‐up was 12.9 years (interquartile range, 6.0–23.4 years) . Incidence rate of SCD in sarcoidosis was 192 (95% CI, 92–352) versus 155 (95% CI, 71–294) in comparators (hazard ratio [HR], 1.28 (95% CI, 0.52–3.17). Nocturnal deaths were more frequent in sarcoidosis 57 (95% CI, 12–168) versus 17 (95% CI, 0.4–95) (HR, 3.76 [95% CI, 0.39–36.47]). No significant differences were detected between the groups by sex, age, calendar year of diagnosis, or disease duration. Conclusions In a population‐based cohort of patients with sarcoidosis, the risk for SCD compared with matched comparators was not increased. There were more nocturnal deaths among patients with sarcoidosis, yet this was statistically insignificant.
Left ventricular assist devices: A historical perspective at the intersection of medicine and engineering
Goodman, Daniel , Stulak, John M., Rosenbaum, Andrew , Rosenbaum, Andrew N

Mayo Clinic

Artificial Organs | August 5, 2022 | Volume: 46 | Issue: 12 | Pages: 2343-2360

10.1111/aor.14371 | PMID 35929377 Get It

AbstractOver the last half‐century, left ventricular assist device (LVAD) technology has progressed from conceptual therapy for failed cardiopulmonary bypass weaning to an accepted destination therapy for advanced heart failure. The history of LVAD engineering is defined by an initial development phase, which demonstrated the feasibility of such an approach, to the more recent three major generations of commercial devices. In this review, we explore the engineering challenges of LVADs, how they were addressed over time, and the clinical outcomes that resulted from each major technological development. The first generation of commercial LVADs were pulsatile devices, which lacked the appropriate durability due to their number of moving components and hemocompatibility. The second generation of LVADs was defined by replacement of complex, pulsatile pumps with primarily axial, continuous‐flow systems with an impeller in the blood passageway. These devices experienced significant commercial success, but the presence of excessive trauma to the blood and in‐situ bearing resulted in an unacceptable burden of adverse events. Third generation centrifugal‐flow pumps use magnetically suspended rotors within the pump chamber. Superior outcomes with this newest generation of devices have been observed, particularly with respect to hemocompatibility‐related adverse events including pump thrombosis, with fully magnetically levitated devices. The future of LVAD engineering includes wireless charging foregoing percutaneous drivelines and more advanced pump control mechanisms, including synchronization of the pump flow with the native cardiac cycle, and varying pump output based on degree of physical exertion using sensor or advanced device‐level data triggers.
A conversation on evidence‐based medicine in the COVID‐era, patient revolution, and academic career with Dr. Victor Montori
Mitra, Souvik , Boasquevisque, Danielle de Sá , Rodrigues, Myanca , Lawson, Daeria O. , Thabane, Lehana , Rodrigues, Myanca , Lawson, Daeria O , Thabane, Lehana , Noorduyn, Stephen G. , Montori, Víctor M.

Mayo Clinic

Journal of Evidence-Based Medicine | August 5, 2022 | Volume: 15 | Issue: 3 | Pages: 187-191

10.1111/jebm.12487 | PMID 35927962 Get It

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
Bravi, Carlo Andrea , Heidenreich, Axel , Gandaglia, Giorgio , Cucchiara, Vito , Osmonov, Daniar , Juenemann, Klaus‐Peter, Karnes, R. Jeffrey , Kretschmer, Alexander , Büchner, Alexander , Hiester, Andreas , Albers, Peter , Joniau, Steven , Shariat, Shahrokh F., Graefen, Markus , Karakiewicz, Pierre I. , Montorsi, Francesco , Briganti, Alberto , Pfister, David, Larcher, Alessandro , Bravi, Carlo A , Gandaglia, Giorgio , Mazzone, Elio , Karnes, Jeffrey , Kretschmer, Alexander , Devos, Gaëtan , Montorsi, Francesco , Pfister, David , Joniau, Steven , Fossati, Nicola , Suardi, Nazareno , Stabile, Armando , Stief, Christian G. , Poppel, Hendrik Van , Grubmüller, Bernhard , Tilki, Derya , Gill, Inderbir S. , Mottrie, Alexandre

Mayo Clinic

BJUI Compass | August 5, 2022 | Volume: 4 | Issue: 1 | Pages: 123-129

10.1002/bco2.182 | PMID 36569505 Get It

AbstractObjectiveTo evaluate the relationship between pre‐operative PSA value, 68Ga‐prostate‐specific‐membrane‐antigen (PSMA) PET performance and oncologic outcomes after salvage lymph node dissection (sLND) for biochemical recurrent prostate cancer (PCa).Patients and methodsThe study included 164 patients diagnosed with ≤2 pelvic lymph‐node recurrence(s) of PCa documented on 68Ga‐PSMA PET scan and treated with pelvic ± retroperitoneal sLND at 11 high‐volume centres between 2012 and 2019. Pathologic findings were correlated to PSA values at time of sLND, categorized in early (<0.5 ng/ml), low (0.5–0.99 ng/ml), moderate (1–1.5 ng/ml) and high (>1.5 ng/ml). Clinical recurrence (CR)‐free survival after sLND was calculated using multivariable analyses and plotted over pre‐operative PSA value.ResultsMedian [interquartile range (IQR)] PSA at sLND was 1.1 (0.6, 2.0) ng/ml, and 131 (80%) patients had one positive spot at PET scan. All patients received pelvic sLND, whereas 91 (55%) men received also retroperitoneal dissection. Median (IQR) number of node removed was 15 (6, 28). The rate of positive pathology increased as a function of pre‐operative PSA value, with highest rates for patients with pre‐operative PSA > 1.5 ng/ml (pelvic‐only sLNDs: 84%; pelvic + retroperitoneal sLNDs: 90%). After sLND, PSA ≤ 0.3 ng/ml was detected in 67 (41%) men. On multivariable analyses, pre‐operative PSA was associated with PSA response (p < 0.0001). There were 51 CRs after sLND. After adjusting for confounders, we found a significant, non‐linear relationship between PSA level at sLND and the 12‐month CR‐free survival (p < 0.0001), with the highest probability of freedom from CR for patients who received sLND at PSA level ≥1 ng/ml.ConclusionsIn case of PET‐detected nodal recurrences amenable to sLND, salvage surgery was associated with the highest short‐term oncologic outcomes when performed in men with PSA ≥ 1 ng/ml. Awaiting confirmatory data from prospective trials, these findings may help physicians to optimize the timing for 68Ga‐PSMA PET in biochemical recurrent PCa.
ACG Clinical Guideline: Gastroparesis
Camilleri, Michael , Vaughn, Vida, Petrey, Jessica , Greer, Katarina B. , Kuo, Braden , Nguyen, Linda Anh B. , Yadlapati, Rena , Abell, Thomas L.

Mayo Clinic

American Journal of Gastroenterology | August 4, 2022 | Volume: 117 | Issue: 8 | Pages: 1197-1220

10.14309/ajg.0000000000001874 | PMID 35926490 Get It

Gastroparesis is characterized by symptoms suggesting retention of food in the stomach with objective evidence of delayed gastric emptying in the absence of mechanical obstruction in the gastric outflow. This condition is increasingly encountered in clinical practice. These guidelines summarize perspectives on the risk factors, diagnosis, and management of gastroparesis in adults (including dietary, pharmacological, device, and interventions directed at the pylorus), and they represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation process. When the evidence was not appropriate for Grading of Recommendations, Assessment, Development, and Evaluation, we used expert consensus to develop key concept statements. These guidelines should be considered as preferred but are not the only approaches to these conditions.
Evolution of Clinical Complexity, Treatment Burden, Health Care Use, and Diabetes-Related Outcomes Among Commercial and Medicare Advantage Plan Beneficiaries With Diabetes in the U.S., 2006–2018
Benning, Tyler J. , Heien, Herbert C., McCoy, Rozalina G.

Mayo Clinic

Diabetes Care | August 4, 2022 | Volume: 45 | Issue: 10 | Pages: 2299-2308

10.2337/dc21-2623 | PMID 35926104 Get It

OBJECTIVE To characterize trends in clinical complexity, treatment burden, health care use, and diabetes-related outcomes among adults with diabetes. RESEARCH DESIGN AND METHODS We used a nationwide claims database to identify enrollees in commercial and Medicare Advantage plans who met claims criteria for diabetes between 1 January 2006 and 31 March 2019 and to quantify annual trends in clinical complexity (e.g., active health conditions), treatment burden (e.g., medications), health care use (e.g., ambulatory, emergency department [ED], and hospital visits), and diabetes-related outcomes (e.g., hemoglobin A1c [HbA1c] levels) between 2006 and 2018. RESULTS Among 1,470,799 commercially insured patients, the proportion with ≥10 active health conditions increased from 33.3% (95% CI 33.1–33.4) in 2006 to 38.9% (38.8–39.1) in 2018 (P = 0.001) and the proportion taking three or more glucose-lowering medications increased from 11.6% (11.5–11.7) to 23.1% (22.9–23.2) (P = 0.007). The proportion with HbA1c ≥8.0% (≥64 mmol/mol) increased from 28.0% (27.7–28.3) in 2006 to 30.5% (30.2–30.7) in 2015, decreasing to 27.8% (27.5–28.0) in 2018 (overall trend P = 0.04). Number of ambulatory visits per patient per year decreased from 6.86 (6.84–6.88) to 6.19 (6.17–6.21), (P = 0.001) while ED visits increased from 0.26 (0.257–0.263) to 0.29 (0.287–0.293) (P = 0.001). Among 1,311,903 Medicare Advantage enrollees, the proportion with ≥10 active conditions increased from 51.6% (51.2–52.0) to 65.1% (65.0–65.2) (P &lt; 0.001); the proportion taking three or more glucose-lowering medications was stable at 16.6% (16.3–16.9) and 18.1% (18.0–18.2) (P = 0.98), and the proportion with HbA1c ≥8.0% increased from 17.4% (16.7–18.1) to 18.6% (18.4–18.7) (P = 0.008). Ambulatory visits per patient per year remained stable at 8.01 (7.96–8.06) and 8.17 (8.16–8.19) (P = 0.23), but ED visits increased from 0.41 (0.40–0.42) to 0.66 (0.66–0.66) (P &lt; 0.001). CONCLUSIONS Among patients with diabetes, clinical complexity and treatment burden have increased over time. ED utilization has also increased, and patients may be using ED services for low-acuity conditions.
Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan
Luo, Jingqin , Agboola, Folasade, Grant, Elizabeth, Morris, John C. , Masters, Colin L. , Albert, Marilyn , Fagan, Anne M. , Hassenstab, Jason , Perrin, Richard J. , Wang, Guoqiao , Li, Yan , Gordon, Brian A. , Day, Gregory S. , Xiong, Chengjie , Vöglein, Jonathan , Suzuki, Kazushi , (DIAN), Dominantly Inherited Alzheimer Network, Gordon, Brian A , Vöglein, Jonathan , Ikeuchi, T , Xiong, Chengjie , Day, Gregory S , Masters, Colin L , Hassenstab, Jason , Morris, John C , Luo, Jingqin , Johnson, Sterling C. , McDade, Eric , Benzinger, Tammie L.S. , Bateman, Randall J. , Cruchaga, Carlos , Ikeuchi, Takeshi , Allegri, Ricardo , Xiong, Chengjie , (DIAN), Dominantly Inherited Alzheimer Network

Mayo Clinic

Brain | August 4, 2022 | Volume: 145 | Issue: 12 | Pages: 4459-4473

10.1093/brain/awac238 | PMID 35925685 Get It

AbstractThe temporal evolutions and relative orderings of Alzheimer disease biomarkers, including CSF amyloid-β42 (Aβ42), Aβ40, total tau (Tau) and phosphorylated tau181 (pTau181), standardized uptake value ratio (SUVR) from the molecular imaging of cerebral fibrillar amyloid-β with PET using the 11C-Pittsburgh Compound-B (PiB), MRI-based hippocampal volume and cortical thickness and cognition have been hypothesized but not yet fully tested with longitudinal data for all major biomarker modalities among cognitively normal individuals across the adult lifespan starting from 18 years. By leveraging a large harmonized database from 8 biomarker studies with longitudinal data from 2609 participants in cognition, 873 in MRI biomarkers, 519 in PET PiB imaging and 475 in CSF biomarkers for a median follow-up of 5–6 years, we estimated the longitudinal trajectories of all major Alzheimer disease biomarkers as functions of baseline age that spanned from 18 to 103 years, located the baseline age window at which the longitudinal rates of change accelerated and further examined possible modifying effects of apolipoprotein E (APOE) genotype. We observed that participants 18–45 years at baseline exhibited learning effects on cognition and unexpected directions of change on CSF and PiB biomarkers. The earliest acceleration of longitudinal change occurred for CSF Aβ42 and Aβ42/Aβ40 ratio (with an increase) and for Tau, and pTau181 (with a decrease) at the next baseline age interval of 45–50 years, followed by an accelerated increase for PiB SUVR at the baseline age of 50–55 years and an accelerated decrease for hippocampal volume at the baseline age of 55–60 years and finally by an accelerated decline for cortical thickness and cognition at the baseline age of 65–70 years. Another acceleration in the rate of change occurred at the baseline age of 65–70 years for Aβ42/Aβ40 ratio, Tau, pTau181, PiB SUVR and hippocampal volume. Accelerated declines in hippocampal volume and cognition continued after 70 years. For participants 18–45 years at baseline, significant increases in Aβ42 and Aβ42/Aβ40 ratio and decreases in PiB SUVR occurred in APOE ɛ4 non-carriers but not carriers. After age 45 years, APOE ɛ4 carriers had greater magnitudes than non-carriers in the rates of change for all CSF biomarkers, PiB SUVR and cognition. Our results characterize the temporal evolutions and relative orderings of Alzheimer disease biomarkers across the adult lifespan and the modification effect of APOE ɛ4. These findings may better inform the design of prevention trials on Alzheimer disease.